JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267164

Human IFI44L knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

IFI44L KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 2 and 5 bp deletion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

C1orf29, GS3686, IF44L_HUMAN, Interferon-induced protein 44-like

2 Images
Sanger Sequencing - Human IFI44L knockout A549 cell line (AB267164)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFI44L knockout A549 cell line (AB267164)

Allele-1 : 16 bp deletion in exon2

Sanger Sequencing - Human IFI44L knockout A549 cell line (AB267164)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFI44L knockout A549 cell line (AB267164)

Allele-2 : 5 bp deletion in exon 2.

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 2 and 5 bp deletion in exon 2

Disease

Carcinoma

Product details

Recommended control: Human wild-type A549 cell line (ab255450). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Properties and storage information

Gene name
IFI44L
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The interferon-induced protein 44-like (IFI44L) is a protein encoded by the IFI44L gene. It is also known as IFI44L protein or sometimes simply IFI44L. This protein has a molecular mass of around 49 kDa. IFI44L is broadly expressed in many tissues with higher expression in blood and spleen. Mechanically IFI44L contributes to the antiviral response by being induced by type I and type II interferons. Its exact mechanism of action involves modulation in response to viral infection although full details of how it works are still not completely understood.
Biological function summary

IFI44L plays an active role in the body's defense against viral infections. It participates as part of the broader immune response. While not being recognized as a classic element of a large protein complex it interacts with cellular machinery responsible for immune regulation and interferon signaling. This protein contributes towards the establishment of an antiviral state in affected cells through mechanisms which are yet to be completely defined. Its inducible nature makes it an important part of how cells respond to foreign viral components.

Pathways

This target connects to the interferon signaling pathway which is important for antiviral defenses. IFI44L plays a significant role in the broader cytokine signaling pathways particularly those related to type I interferon responses. It interacts with proteins such as MX1 and IFIT1 which are important elements of the interfacing network that responds to viral challenges in the cell. These relationships help in sustaining a robust antiviral state within the host.

IFI44L is linked to conditions like systemic lupus erythematosus (SLE) and viral infections such as hepatitis C. This can be due to its regulatory role in immune responses and interferon signaling. In SLE where interferon activity is often dysregulated IFI44L expression can be elevated. It also connects with proteins like IFI27 and ISG15 which are similarly upregulated in response to viral infections and are implicated in the pathogenesis of these diseases. Understanding IFI44L's function and interactions further aids in exploring therapeutic approaches for these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com